| DC5114 |
Apixaban (BMS 562247-01)
Featured
|
Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. |
|
| DC8004 |
AZD6482
Featured
|
AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ. |
|
| DC7373 |
Betrixaban
Featured
|
Betrixaban (PRT-054021) is a highly potent, selective, and orally efficacious factor Xa inhibitor with IC50 of 1.2 nM(inhibition of Factor 10a). |
|
| DCAPI1112 |
BIBR 953(Dabigatran)
Featured
|
BIBR 953 (Dabigatran, Pradaxa) is a highly selective, reversible, and potent thrombin inhibitor and is orally available as the prodrug, dabigatran etexilate. |
|
| DC1010 |
BIBR-1048 (Dabigatran etexilate)
Featured
|
BIBR-1048 (Dabigatran) is an anticoagulant from the class of the direct thrombin inhibitors. |
|
| DC11923 |
BMS-986120
Featured
|
BMS-986120 (BMS986120) is a potent, selective, orally bioavailable, and reversible PAR4 antagonist with Kd of 0.098 nM for human PAR4. |
|
| DC7005 |
Cangrelor free acid
Featured
|
Cangrelor is a P2Y12 inhibitor, and was approved in June 2015 as an antiplatelet drug for intravenous application. Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggrega |
|
| DC3147 |
Clopidogrel hydrogensulfate |
Clopidogrel (Plavix) is an oral, thienopyridine class antiplatelet agent. |
|
| DCAPI1417 |
Clopidogrel |
Clopidogrel is an irreversible inhibitor of the P2Y12 receptor, which is responsible for initiating signal transduction via a GPCR. The signal cascade initiates platelet aggregation and thus clopidogrel has the effect of “thinning” the blood. |
|
| DC8913 |
Dabigatran etexilate mesylate
Featured
|
Dabigatran etexilate mesylate (BIBR 1048MS) is the orally active prodrug of dabigatran. Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM. |
|
| DC8533 |
E5555 hydrobromide |
E5555 shows potent inhibitory effects on human platelet aggregation induced by thrombin and TRAP with IC values of 0.064 and 0.031 μM respectively. |
|
| DC8305 |
Edoxaban
Featured
|
Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention |
|
| DC8793 |
Edoxaban tosylate monohydrate
Featured
|
Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention |
|
| DC7772 |
Elinogrel |
Elinogrel is a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. |
|
| DC9443 |
Otamixaban |
Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.
|
|
| DC10500 |
PF-06282999
Featured
|
PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases. |
|
| DC5108 |
BAY 59-7939 (Rivaroxaban)
Featured
|
Rivaroxaban (Xarelto; BAY 59-7939) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders. |
|
| DC1101 |
Ticagrelor (Brilinta,AZD6140)
Featured
|
Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist, also inhibits CYP2C9 and 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively. |
|
| DC9489 |
Tirofiban (hydrochloride monohydrate)
Featured
|
Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist
|
|
| DC7327 |
Tirofiban(L700462;MK383)
Featured
|
Tirofiban(L700462;MK383) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist. |
|
| DC8860 |
Vorapaxar
Featured
|
Vorapaxar (SCH 530348) is a potent and orally active thrombin receptor (PAR-1) antagonist with Ki of 8.1 nM. |
|
